DOCSLIB.ORG

Study Protocol);

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

PF-06826647 C2501001 Final Protocol Amendment 3, 05April 2018 A PHASE 1, WITHIN COHORT, RANDOMIZED, DOUBLE BLIND, THIRD-PARTY OPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE DOSE ESCALATION, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF-06826647 IN HEALTHY SUBJECTS AND SUBJECTS WITH PLAQUE PSORIASIS Investigational Product Number: PF-06826647 Investigational Product Name: Not Available (N/A) United States (US) Investigational New CCI Drug (IND) Number: European Clinical Trials Database N/A (EudraCT) Number: Protocol Number: C2501001 Phase: 1 Page 1 PF-06826647 C2501001 Final Protocol Amendment 3, 05April 2018 Document History Document Version Date Summary of Changes and Rationale Amendment 3 05 April 2018 Section 1.3.2: updated the preliminary summary of clinical experience with PF-06826647. Sections 1.3.2 and 1.3.4.1: dose rationale updated with preliminary pharmacokinetic (PK) parameters and starting dose selection rationale for psoriasis cohorts. Section 3.1.1 and 3.1.2: introduction of optional cohort of Japanese subjects for PK comparability to support the clinical development plan for PF-06826647. Section 3.1.2: added text indicating that PF-06826647 dose level may be adjusted for the second psoriasis cohort based on emerging clinical data from the planned interim analysis, at the discretion of the Sponsor. Figure 1: Study Schematic updated with planned psoriasis cohort PF-06826647 dose level (based on recent psoriasis dose selection), dose level for the optional twice daily dose regimen cohort (BID), and optional Japanese cohort. Figure 2: legend updated to add optional Japanese cohort. Section 5.2: edits made to indicate that psoriasis cohorts will be sponsor-open, in order to allow sponsor review interim analysis results to inform dose decisions for psoriasis Cohort 2 PF-06826647 dose level. Section 4.1, Healthy Subject Inclusion Criteria: added single criterion for optional Japanese subject eligibility. Section 6.1: expanded the maximum duration of the screening period from 28 to 45 days for psoriasis subjects, in order to accommodate potential recruitment delays in between cohorts, while Sponsor reviews results from the interim Page 2 PF-06826647 C2501001 Final Protocol Amendment 3, 05April 2018 analysis of psoriasis area and severity index scores. Section 7, Table 7: added creatine phosphokinase laboratory test to the chemistry panel for psoriasis subjects, to help ensure adequate safety monitoring for subjects receiving longer duration of treatment (ie, 28 days). Section 9.7: added interim analysis of key secondary PASI endpoint for the 400 mg psoriasis cohort, to be conducted when 21 subjects complete through study Day 28, to inform dose selection for subsequent psoriasis cohort and to support clinical development decisions for PF-06826647. Section 9.7: changed the planned psoriasis cohorts from sponsor blind to sponsor-open, in order to permit review of interim analysis results by a designated, limited number of sponsor colleagues to facilitate dose selection adjustment/decisions for psoriasis Cohort 2. Several administrative edits and minor clarifications made. Amendment 2 20 December 2017 Schedule of Activities: Healthy Subject Single and Multiple Ascending Dose Periods. Added a blood sample collection on Day 8 of the single asending dose period, in order to adequately characterize the pharmacokinetic (PK) profile (terminal half-life) of PF-06826647. Removed a PK blood sample on Day 1, 16 hours post dose to avoid increasing blood volume requirements for subjects. Added a study visit on Day 17 for extended PK sample collection (with corresponding vital sign collection and adverse event monitoring), in order to adequately characterize the terminal half-life of PF-06826647. Removed the Day 1 and Day 10, 16 hour post-dose blood collection for PK assessment to avoid increasing blood volume requirements for subjects. Page 3 PF-06826647 C2501001 Final Protocol Amendment 3, 05April 2018 The rationale for the above changes is based on emerging PK data from the C2501001 trial, which indicates that the terminal half-life of PF-06826647 may be dose dependent. The proposed PK sampling at approximately 168 hours post dose will help to fully characterize the PK profile of PF-06826647. Section 1.3.2: Updated the preliminary summary of clinical experience. Section 3.1.1 Study design- healthy subject single and multiple ascending dose period: extended the wash-out period between SAD and MAD dosing from 7 days to 14 days, based on preliminary assessment of the potential dose depenedent terminal half-life of PF-06826647. Section 3.1.1 and 3.2 – added language to the dose escalation paradigm to state that the highest dose to be tested in MAD will not exceed the highest dose tested in SAD cohort, and that he highest dose MAD cohort will commence if adequate safety is demonstrated in SAD cohort at the same or higher dose level and the projected exposure at steady state does not exceed NOAEL. Amendment 1 06 November 2017 Various administrative changes. Schedule of activities: removed the Day 28 blood collection for viral surveillance from the multiple ascending dose period, added additional blood collection for pharmacokinetic (PK) assessment on Day 1. Schedule of activities: removed the Day 7 and Day 56 blood collection for viral surveillance from the Psoriasis Cohort schedule. CCI Page 4 PF-06826647 C2501001 Final Protocol Amendment 3, 05April 2018 CCI Schedule of activities: added additional electrocardiogram (ECG) and vital sign assessment on Day 1 of the multiple ascending dose period, to coincide with the revised Day 1 PK collection. Section 1.3.2 Preliminary Summary of Clinical Experience added to provide rationale for revised PF-06826647 dose levels in the single and multiple ascending dose periods. Section 1.3.4 Updated Dose Rationale Based on Emerging Clinical Data added to provide rationale for revised PF-06826647 dose levels in the single and multiple ascending dose (MAD) periods. Section 3.1.1 Healthy Subject Single and Multiple Ascending Dose Periods, updated PF-06826647 dose levels based on emerging PK data from the C2501001 study, and added optional cohorts to further explore higher PF-06826647 exposure ranges. Figure 1 Study Schematic, updated to reflect amendment 1 PF-06826647 dose levels and addition of optional cohorts to further explore higher PF-06826647 exposure ranges. Section 4.6.1 Meals and Dietary Requirements, updated to specify revised meal requirements for the multiple ascending dose period and psoriasis cohorts (dosing with food based on the emerging PK data from Study C2501001). Section 5.5 Administration, harmonized with Protocol Section 4.6.1 to reflect the revised meal requirements for the trial. Section 6.1 Screening, updated screening window Page 5 PF-06826647 C2501001 Final Protocol Amendment 3, 05April 2018 to allow eligible healthy subjects entry into the trial after lapse of the 28 day screening period, assuming study Day -1 paramters are within the limits of eligibility, as defined in Protocol Section 4. Section 7.10 Blood Volume, updated blood volume table to reflect reduced viral surveillance testing, and added PK sample collection on Day 1 of the MAD period. Section 7.11.1 CCI clarified process for management of subjects at Screening visit, in accordance with site Institutional Review Board (IRB) request. Original 16 May 2017 N/A protocol This amendment incorporates all revisions to date, including amendments made at the request of country health authorities and institutional review boards (IRBs)/ethics committees (ECs). Page 6 PF-06826647 C2501001 Final Protocol Amendment 3, 05April 2018 TABLE OF CONTENTS LIST OF TABLES...................................................................................................................13 LIST OF FIGURES .................................................................................................................13 APPENDICES .........................................................................................................................13 SCHEDULE OF ACTIVITIES................................................................................................15 1. INTRODUCTION ...............................................................................................................25 1.1. Mechanism of Action/Indication.............................................................................25 1.2. Background .............................................................................................................25 1.2.1. Binding to the Pharmacological Target ......................................................25 1.2.2. Cellular Potency and Selectivity.................................................................26 1.2.3. Non-Clinical Pharmacokinetics and Metabolism .......................................28 1.2.4. Non-clinical Safety Studies ........................................................................29 1.2.5. Biopharmaceutics Properties ......................................................................32 1.3. Rationale..................................................................................................................32 1.3.1. Study Rationale...........................................................................................32 1.3.2. Preliminary Summary of Clinical Experience............................................33 1.3.3. Dose Rationale............................................................................................34
Recommended publications
  • LYSODREN Safely and Effectively

    LYSODREN Safely and Effectively

    HIGHLIGHTS OF PRESCRIBING INFORMATION -----------------------WARNINGS AND PRECAUTIONS------------------------ These highlights do not include all the information needed to use • Central Nervous System (CNS) Toxicity: Plasma concentrations LYSODREN safely and effectively. See full prescribing information for exceeding 20 mcg/mL are associated with a greater incidence of toxicity. LYSODREN. (5.2) • Adrenal Insufficiency: Institute steroid replacement as clinically LYSODREN® (mitotane) tablets, for oral use indicated. Measure free cortisol and corticotropin (ACTH) levels to Initial U.S. Approval: 1970 achieve optimal steroid replacement. (5.3) • Embryo-Fetal Toxicity: Can cause fetal harm. Advise women of WARNING: ADRENAL CRISIS IN THE SETTING OF SHOCK OR reproductive potential of the potential risk to a fetus and use of effective SEVERE TRAUMA contraception. (5.4, 8.1, 8.3) See full prescribing information for complete boxed warning. • Ovarian Macrocysts in Premenopausal Women: Advise women to seek medical advice if they experience gynecological symptoms such as In patients taking LYSODREN, adrenal crisis occurs in the setting of vaginal bleeding and/or pelvic pain. (5.5) shock or severe trauma and response to shock is impaired. Administer hydrocortisone, monitor for escalating signs of shock and discontinue -------------------------------ADVERSE REACTIONS------------------------------ LYSODREN until recovery. (2.2, 5.1) Common adverse reactions (≥15%) include: anorexia, nausea, vomiting and diarrhea; depression, dizziness or vertigo; and rash. (6) ---------------------------INDICATIONS AND USAGE---------------------------- LYSODREN is an adrenal cytotoxic agent indicated for the treatment of To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers inoperable, functional or nonfunctional, adrenal cortical carcinoma. (1) Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
  • EDP & Mitotane Protocol

    EDP & Mitotane Protocol

    THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST Systemic Anti Cancer Treatment Protocol EDP + mitotane PROCEDURE REF: MPHA HANEDP (Version No: 1.0) Approved for use in: Symptomatic treatment for advanced (unresectable, metastatic or relapsed) adrenocortical carcinoma ECOG performance status of 0 - 2 All possible tumour tissues should be surgically removed from large metastatic masses before mitotane administration is instituted. This is necessary to minimise the possibility of infarction and haemorrhage in the tumour due to a rapid cytotoxic effect of mitotane Exclusion criteria: Previous complete cumulative doses of anthracyclines Decompensated heart failure (ejection fraction <50%) Unstable angina, uncontrolled cardiac arrhythmias, MI or revascularisation procedure within last 6 months Dosage: Drug Dosage Route Frequency Etoposide 100mg/m2 IV Daily on days 2, 3 and 4 of each cycle Doxorubicin 40mg/m2 IV Once only on day 1 of each cycle Cisplatin 40mg/m2 IV Daily on days 3 and 4 of each cycle Variable, max Continuous, started a week prior to IV Mitotane PO 6g daily chemotherapy if not already taking With cycles repeated at 28 day intervals until disease progression Supportive treatments: Domperidone 10mg oral tablets maximum 3 times a day or as required Issue Date: May 2017 Page 1 of 8 Protocol reference: MPHAHANEDP 1 Authorised by: Drugs & Therapeutics Author: Helen Flint Committee & Dr D Husband Version No: 1.0 THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST Extravasation risk: Doxorubicin is a vesicant and must be observed during administration. Follow the procedure for anthracycline extravasation. Erythematous streaking (a histamine release phenomenon) along the vein proximal to the site of injection has been reported, and must be differentiated from an extravasation event.
  • Study Protocol and Statistical Analysis Plan

    Study Protocol and Statistical Analysis Plan

    Confidential Clinical study protocol number: J1228 Page 1 Version Date: May 7, 2018 IRB study Number: NA_00067315 A Trial of maintenance Rituximab with mTor inhibition after High-dose Consolidative Therapy in CD20+, B-cell Lymphomas, Gray Zone Lymphoma, and Hodgkin’s Lymphoma Principal Investigator: Douglas E. Gladstone, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 1650 Orleans Street, CRBI-287 Baltimore, MD 21287 Phone: 410-955-8781 Fax: 410-614-1005 Email: [email protected] IRB Protocol Number: NA_00067315 Study Number: J1228 IND Number: EXEMPT Novartis Protocol Number: CRAD001NUS157T Version: May 7, 2018 Co-Investigators: Jonathan Powell 1650 Orleans Street, CRBI-443 Phone: 410-502-7887 Fax: 443-287-4653 Email: [email protected] Richard Jones 1650 Orleans Street, CRBI-244 Phone: 410-955-2006 Fax: 410-614-7279 Email: [email protected] Confidential Clinical study protocol number: J1228 Page 2 Version Date: May 7, 2018 IRB study Number: NA_00067315 Satish Shanbhag Johns Hopkins Bayview Medical Center 301 Building, Suite 4500 4940 Eastern Ave Phone: 410-550-4061 Fax: 410-550-5445 Email: [email protected] Statisticians: Gary Rosner Phone: 410-955-4884 Email: [email protected] Marianna Zahurak Phone: 410-955-4219 Email: [email protected] Confidential Clinical study protocol number: J1228 Page 3 Version Date: May 7, 2018 IRB study Number: NA_00067315 Table of contents Table of contents ......................................................................................................................... 3 List of abbreviations
  • Targeting the Mitochondrial Metabolic Network: a Promising Strategy in Cancer Treatment

    Targeting the Mitochondrial Metabolic Network: a Promising Strategy in Cancer Treatment

    International Journal of Molecular Sciences Review Targeting the Mitochondrial Metabolic Network: A Promising Strategy in Cancer Treatment Luca Frattaruolo y , Matteo Brindisi y , Rosita Curcio, Federica Marra, Vincenza Dolce and Anna Rita Cappello * Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Via P. Bucci, 87036 Rende (CS), Italy; [email protected] (L.F.); [email protected] (M.B.); [email protected] (R.C.); [email protected] (F.M.); [email protected] (V.D.) * Correspondence: [email protected] These authors contributed equally and should be considered co-first authors. y Received: 31 July 2020; Accepted: 19 August 2020; Published: 21 August 2020 Abstract: Metabolic reprogramming is a hallmark of cancer, which implements a profound metabolic rewiring in order to support a high proliferation rate and to ensure cell survival in its complex microenvironment. Although initial studies considered glycolysis as a crucial metabolic pathway in tumor metabolism reprogramming (i.e., the Warburg effect), recently, the critical role of mitochondria in oncogenesis, tumor progression, and neoplastic dissemination has emerged. In this report, we examined the main mitochondrial metabolic pathways that are altered in cancer, which play key roles in the different stages of tumor progression. Furthermore, we reviewed the function of important molecules inhibiting the main mitochondrial metabolic processes, which have been proven to be promising anticancer candidates in recent years. In particular, inhibitors of oxidative phosphorylation (OXPHOS), heme flux, the tricarboxylic acid cycle (TCA), glutaminolysis, mitochondrial dynamics, and biogenesis are discussed. The examined mitochondrial metabolic network inhibitors have produced interesting results in both preclinical and clinical studies, advancing cancer research and emphasizing that mitochondrial targeting may represent an effective anticancer strategy.
  • Daidzein and Genistein Content of Cereals

    Daidzein and Genistein Content of Cereals

    European Journal of Clinical Nutrition (2002) 56, 961–966 ß 2002 Nature Publishing Group All rights reserved 0954–3007/02 $25.00 www.nature.com/ejcn ORIGINAL COMMUNICATION Daidzein and genistein content of cereals J Liggins1, A Mulligan1,2, S Runswick1 and SA Bingham1,2* 1Medical Research Council Dunn Human Nutrition Unit, Hills Road, Cambridge, UK; and 2European Prospective Investigation of Cancer, University of Cambridge, Cambridge, UK Objective: To analyse 75 cereals and three soy flours commonly eaten in Europe for the phytoestrogens daidzein and genistein. Design: The phytoestrogens daidzein and genistein were extracted from dried foods, and the two isoflavones quantified after hydrolytic removal of any conjugated carbohydrate. Completeness of extraction and any procedural losses of the isoflavones 0 0 were accounted for using synthetic daidzin (7-O-glucosyl-4 -hydroxyisoflavone) and genistin (7-O-glucosyl-4 5-dihydroxyiso- flavone) as internal standards. Setting: Foods from the Cambridge UK area were purchased, prepared for eating, which included cooking if necessary, and freeze dried. Three stock soy flours were also analysed. Results: Eighteen of the foods assayed contained trace or no detectable daidzein or genistein. The soy flours were rich sources, containing 1639 – 2117 mg=kg. The concentration of the two isoflavones in the remaining foods ranged from 33 to 11 873 mg=kg. Conclusion: These analyses will supply useful information to investigators determining the intake of phytoestrogens in cereal products in order to relate intakes to potential biological activities. Sponsorship: This work was supported by the United Kingdom Medical Research Council, Ministry of Agriculture Fisheries and Food (contract FS2034) and the United States of America Army (contract DAMD 17-97-1-7028).
  • BC Cancer Benefit Drug List September 2021

    BC Cancer Benefit Drug List September 2021

    Page 1 of 65 BC Cancer Benefit Drug List September 2021 DEFINITIONS Class I Reimbursed for active cancer or approved treatment or approved indication only. Reimbursed for approved indications only. Completion of the BC Cancer Compassionate Access Program Application (formerly Undesignated Indication Form) is necessary to Restricted Funding (R) provide the appropriate clinical information for each patient. NOTES 1. BC Cancer will reimburse, to the Communities Oncology Network hospital pharmacy, the actual acquisition cost of a Benefit Drug, up to the maximum price as determined by BC Cancer, based on the current brand and contract price. Please contact the OSCAR Hotline at 1-888-355-0355 if more information is required. 2. Not Otherwise Specified (NOS) code only applicable to Class I drugs where indicated. 3. Intrahepatic use of chemotherapy drugs is not reimbursable unless specified. 4. For queries regarding other indications not specified, please contact the BC Cancer Compassionate Access Program Office at 604.877.6000 x 6277 or [email protected] DOSAGE TUMOUR PROTOCOL DRUG APPROVED INDICATIONS CLASS NOTES FORM SITE CODES Therapy for Metastatic Castration-Sensitive Prostate Cancer using abiraterone tablet Genitourinary UGUMCSPABI* R Abiraterone and Prednisone Palliative Therapy for Metastatic Castration Resistant Prostate Cancer abiraterone tablet Genitourinary UGUPABI R Using Abiraterone and prednisone acitretin capsule Lymphoma reversal of early dysplastic and neoplastic stem changes LYNOS I first-line treatment of epidermal
  • Simultaneous Determination of Daidzein, Genistein and Formononetin in Coffee by Capillary Zone Electrophoresis

    Simultaneous Determination of Daidzein, Genistein and Formononetin in Coffee by Capillary Zone Electrophoresis

    separations Article Simultaneous Determination of Daidzein, Genistein and Formononetin in Coffee by Capillary Zone Electrophoresis Feng Luan *, Li Li Tang, Xuan Xuan Chen and Hui Tao Liu College of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, China; [email protected] (L.L.T.); [email protected] (X.X.C.); [email protected] (H.T.L.) * Correspondence: fl[email protected]; Tel.: +86-535-6902063 Academic Editor: Doo Soo Chung Received: 29 October 2016; Accepted: 20 December 2016; Published: 1 January 2017 Abstract: Coffee is a favorite and beverage in Western countries that is consumed daily. In the present study, capillary zone electrophoresis (CE) was applied for the separation and quantification of three isoflavones including daidzein, genistein and formononetin in coffee. Extraction of isoflavones from the coffee sample was carried out by extraction and purification process using ether after the acid hydrolysis with the antioxidant butylated hydroxy-toluene (BHT). The experimental conditions of the CE separation method were: 20 mmol/L Na2HPO4 buffer solution, 25 kV applied voltage, 3 s hydrodynamic injection at 30 mbar, and UV detection at 254 nm. The results show that the three compounds can be tested within 10 min with a linearity of 0.5–50 µg/mL for all three compounds. The limits of detection were 0.0642, 0.134, and 0.0825 µg/mL for daidzein, formononetin and genistein, respectively. The corresponding average recovery was 99.39% (Relative Standard Detection (RSD) = 1.76%), 98.71% (RSD = 2.11%) and 97.37% (RSD = 3.74%). Keywords: capillary zone electrophoresis (CE); daidzein; genistein; formononetin; acid hydrolysis 1.
  • Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient with Metastatic Adrenocortical Carcinoma

    Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient with Metastatic Adrenocortical Carcinoma

    CASE REPORT published: 22 April 2021 doi: 10.3389/fendo.2021.674039 Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma † † Deborah Cosentini 1 , Antonella Turla 1 , Ornella Carminati 2, Salvatore Grisanti 1, Vittorio Domenico Ferrari 1, Marta Laganà 1, Giovanni Rosti 3, Sandra Sigala 4 and Alfredo Berruti 1* 1 Medical Oncology Unit, Azienda Socio Sanitaria Territoriale (ASST) Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy, 2 Medical Oncology, Department of Edited by: Oncology and Hematology, Azienda Unità Sanitaria Locale (AUSL), Romagna, Ravenna, Italy, 3 Medical Oncology, Barbara Altieri, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, 4 Section of Pharmacology, Department of Molecular and Translational University Hospital of Wuerzburg, Medicine, University of Brescia, Brescia, Italy Germany Reviewed by: Background: In a recently published retrospective case series, Temozolomide was found Peter Igaz, Semmelweis University, Hungary active as second line approach in advanced ACC patients. The disease control rate obtained, Jaydira Del Rivero, however, was short-lived. We report here an ACC patient with extensive metastatic disease National Cancer Institute (NIH), who obtained a remarkable long lasting response with this alkylating agent. United States *Correspondence: Case Presentation: a 22-year-old female patient with ACC presented at our Medical Alfredo Berruti Oncology Department in poor general condition due the presence of extensive metastatic [email protected] pulmonary involvement. The disease had progressed to etoposide, doxorubicin and † These authors have contributed cisplatin plus mitotane therapy. Second line temozolomide therapy was prescribed equally to this work and share first authorship leading to a progressive improvement of patient general conditions.
  • Soy Isoflavone Genistein Inhibits an Axillary Osmidrosis Risk Factor ABCC11: in Vitro Screening and Fractional Approach for ABCC11-Inhibitory Activities in Plant Extracts and Dietary

    Soy Isoflavone Genistein Inhibits an Axillary Osmidrosis Risk Factor ABCC11: in Vitro Screening and Fractional Approach for ABCC11-Inhibitory Activities in Plant Extracts and Dietary

    nutrients Article Soy Isoflavone Genistein Inhibits an Axillary Osmidrosis Risk Factor ABCC11: In Vitro Screening and Fractional Approach for ABCC11-Inhibitory Activities in Plant Extracts and Dietary Flavonoids 1,2, 2, , 1 1 1 Hiroki Saito y, Yu Toyoda * y , Hiroshi Hirata , Ami Ota-Kontani , Youichi Tsuchiya , Tappei Takada 2 and Hiroshi Suzuki 2 1 Frontier Laboratories for Value Creation, Sapporo Holdings Ltd., 10 Okatome, Yaizu, Shizuoka 425-0013, Japan; [email protected] (H.S.); [email protected] (H.H.); [email protected] (A.O.-K.); [email protected] (Y.T.) 2 Department of Pharmacy, The University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan; [email protected] (T.T.); [email protected] (H.S.) * Correspondence: [email protected] These authors contributed equally to this work. y Received: 2 July 2020; Accepted: 12 August 2020; Published: 14 August 2020 Abstract: Axillary osmidrosis (AO) is a common chronic skin condition characterized by unpleasant body odors emanating from the armpits, and its aetiology is not fully understood. AO can seriously impair the psychosocial well-being of the affected individuals; however, no causal therapy has been established for it other than surgical treatment. Recent studies have revealed that human ATP-binding cassette transporter C11 (ABCC11) is an AO risk factor when it is expressed in the axillary apocrine glands—the sources of the offensive odors. Hence, identifying safe ways to inhibit ABCC11 may offer a breakthrough in treating AO. We herein screened for ABCC11-inhibitory activities in 34 natural products derived from plants cultivated for human consumption using an in vitro assay system to measure the ABCC11-mediated transport of radiolabeled dehydroepiandrosterone sulfate (DHEA-S—an ABCC11 substrate).
  • Kaempferol Exhibits Progestogenic Effects in Ovariectomized Rats May Fern Toh, Emma Mendonca, Sharon L

    Kaempferol Exhibits Progestogenic Effects in Ovariectomized Rats May Fern Toh, Emma Mendonca, Sharon L

    s & H oid orm er o t n S f a l o S l c a Journal of i n e r n u c o e J Toh et al., J Steroids Horm Sci 2014, 5:3 ISSN: 2157-7536 Steroids & Hormonal Science DOI: 10.4172/2157-7536.1000136 Research Article Open Access Kaempferol Exhibits Progestogenic Effects in Ovariectomized Rats May Fern Toh, Emma Mendonca, Sharon L. Eddie, Michael P. Endsley, Daniel D. Lantvit, Pavel A. Petukhov, and Joanna E. Burdette* Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL 60607, USA *Corresponding author: Joanna E. Burdette, 900 S. Ashland Street (M/C 870) Chicago, IL 60607, USA, Tel: 312-996-6153; Fax: 312-996-7107; E-mail: [email protected] Received date: April 15, 2014, Accepted date: June 26, 2014, Published date: July 02, 2014 Copyright: © 2014 Toh MF, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Objective: Progesterone (P4) plays a central role in women's health. Synthetic progestins are used clinically in hormone replacement therapy (HRT), oral contraceptives, and for the treatment of endometriosis and infertility. Unfortunately, synthetic progestins are associated with side effects, including cardiovascular disease and breast cancer. Botanical dietary supplements are widely consumed for the alleviation of a variety of gynecological issues, but very few studies have characterized natural compounds in terms of their ability to bind to and activate progesterone receptors (PR).
  • For Health Professionals Who Care for Cancer Patients

    For Health Professionals Who Care for Cancer Patients

    November 2014 Volume 17, Number 11 For Health Professionals Who Care For Cancer Patients Inside This Issue: . Editor’s Choice – New Programs: nab-Paclitaxel and . Provincial Systemic Therapy Program – Reformat of Gemcitabine for Pancreatic Cancer, Neoadjuvant Paclitaxel BCCA Policy on Prevention and Management of and AC for Breast Cancer, Chlorambucil plus Rituximab for Extravasation of Chemotherapy Lymphomas, Chemotherapy plus Mitotane for . Drug Update – Enzalutamide Patient Assistance Adrenocortical Cancer Program . Cancer Drug Manual – Revised: Filgrastim, Gemcitabine, . List of New and Revised Protocols, Provincial Pre- Oxaliplatin, Paclitaxel, nab-Paclitaxel, Dexamethasone Printed Orders and Patient Handouts – New: . Medication Safety – Improving Website Clarity for Protocol BRLATACG, BRLATWAC, UGIPGEMABR, GUEDPM, Selection LYCHLRR Revised: BRAVEVEX, UCNBEV, GICIRB, . Benefit Drug List – New: BRLATACG, BRLATWAC, GIFFIRB, UGIFFOXB, UGIFIRINOX, GOCXCRT, GOENDH, UGIPGEMABR, GUEDPM, LYCHLRR Revised: ULYRMTN GUPLHRH, GUSCPE, HNAVP, LYIVACR, HNLAPRT, Deleted: BRLAACTW ULKATOATRA, ULKATOP, ULKATOR, ULUAVAFAT, LYABVD, LYCHOP, LYCHOPR, LYCHOPRMTX, LYRMTN . Continuing Professional Development – Workshop on Deleted: BRLAACTW Education in Palliative and End of Life Care for Oncology . Website Resources and Contact Information EDITOR’S CHOICE NEW PROGRAMS The Provincial Systemic Therapy Program has approved the following programs effective 1 November 2014: nab-Paclitaxel (ABRAXANE®) and Gemcitabine for Locally Advanced and Metastatic Pancreatic
  • Inhibitory Effect of Genistein and Daidzein on Ovarian Cancer Cell Growth

    Inhibitory Effect of Genistein and Daidzein on Ovarian Cancer Cell Growth

    ANTICANCER RESEARCH 24: 795-800 (2004) Inhibitory Effect of Genistein and Daidzein on Ovarian Cancer Cell Growth CICEK GERCEL-TAYLOR, ANNA K. FEITELSON and DOUGLAS D. TAYLOR Department of Obstetrics, Gynecology and Women’s Health, University of Louisville, School of Medicine, Louisville, KY 40202, U.S.A. Abstract. Background: Survival from ovarian cancer has not Genistein, a soy isoflavanoid, has been intensely studied changed significantly in the past twenty years requiring in relation to breast cancer. Interest first arose upon development of additional treatment protocols. We studied the discovery of the vast difference in breast cancer rates in effect of genistein and daidzein on ovarian cancer cell growth. Asia versus Western countries (1). Large dietary differences Materials and Methods: Five ovarian cancer cell lines from Stage exist, especially in genistein consumption, as the average IIIC disease were evaluated. Sulforhodamine B and colony Asian intake is 20-80 mg/day whereas the average US intake formation assays were used to analyze growth inhibitory effects of is only 1-3 mg (2,3) The dietary and disease discrepancy genistein and daidzein alone and with cisplatin, paclitaxel or prompted further study into the chemopreventive and topotecan. Apoptosis induction was studied by determining potentially therapeutic properties of genistein. caspase-3 activity. Results: Inhibition of growth (50-80%), colony Genistein has been found to inhibit cell proliferation, formation and colony size was seen at 144 Ìm of genistein, 0-23% oncogenesis and clonogenic ability in animal and human reduction was demonstrated at 9 Ìm. At 144 Ìm, the colony size cells (3-5). Several studies have been performed to evaluate was inhibited >75%; at 9 Ìm 4/5 cell lines had >50% reduction.